Resistance patterns with tyrosine kinase inhibitors in melanoma: new insights.

Abstract

PURPOSE OF REVIEW:

After years of therapeutic approaches with limited effects in metastatic melanoma, new inhibitors of serine-threonine and tyrosine kinases have demonstrated impressive clinical efficacy and improved survival.

RECENT FINDINGS:

This review explains the molecular background for the development of specific kinase inhibitors and briefly summarizes their clinical impact on advanced melanoma.

SUMMARY:

Despite robust early clinical efficacy, the antiproliferative effect of these kinase inhibitors is limited. The resistance mechanisms are explored currently and will help to identify new targets for melanoma therapy.

• Authors: Reinhard Dummer, Keith T Flaherty
• Journal: Current opinion in oncology (Curr Opin Oncol) Vol. 24 Issue 2 Pg. 150-4 (Mar 2012) ISSN: 1531-703X [Electronic] United States
• PMID: 22316627 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Review)

Chemical References

• Antineoplastic Agents
• Indoles
• Protein Kinase Inhibitors
• Sulfonamides
• Vemurafenib
• BRAF protein, human
• Protein Serine-Threonine Kinases
• Proto-Oncogene Proteins B-raf

Topics

• Antineoplastic Agents (therapeutic use)
• Drug Resistance, Neoplasm (genetics)
• Genes, ras (genetics)
• Humans
• Indoles (therapeutic use)
• Melanoma (drug therapy, genetics)
• Protein Kinase Inhibitors (therapeutic use)
• Protein Serine-Threonine Kinases (antagonists & inhibitors)
• Proto-Oncogene Proteins B-raf (genetics)
• Skin Neoplasms (drug therapy, genetics)
• Sulfonamides (therapeutic use)
• Vemurafenib